Advertisement
Screener

Moleculin Biotech, Inc. (MBRX) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

2.8 / 5 stars · 68/120 Roast Me

Moleculin Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

Moleculin Biotech, Inc. (MBRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 1.20 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.

Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-03-18

  • Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2020-12-31 was -16.67K shares.
  • Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2020-09-30 was 0.00 shares.
  • Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2019-12-31 was 0.00 shares.
  • Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2018-12-31 was 0.00 shares.
  • Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.20K shares, a 81.93% decline from fiscal 2024.
  • Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 6.66K shares, a 84.60% increase from fiscal 2023.
  • Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 3.61K shares, a 38.12% decline from fiscal 2022.
  • Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 5.83K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month
2025-12-311.20K shares
10-K · filed 2026-03-18
2024-12-316.66K shares
10-K · filed 2025-03-21
2023-12-313.61K shares
10-K · filed 2024-03-22
2022-12-315.83K shares
10-K · filed 2023-03-22
2021-12-310.00 shares
10-K · filed 2022-03-24
2020-12-31-16.67K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24
-16.67K shares
derived: sum of 2 quarters · filed 2021-03-24
3.33K shares
10-K · filed 2021-03-24
2020-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
20.00K shares
10-Q · filed 2020-11-12
2020-06-3020.00K shares
10-Q · filed 2020-08-12
2019-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19
103.00K shares
10-K · filed 2020-03-19
2019-09-30103.00K shares
10-Q · filed 2019-11-12
2018-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21
5.00K shares
10-K · filed 2019-02-21
2018-09-305.00K shares
10-Q · filed 2018-11-13
2017-12-310.00 shares
10-K · filed 2018-03-28
2017-03-310.00 shares
10-Q · filed 2017-05-12
0.00 shares
derived: sum of 2 quarters · filed 2018-03-28
2016-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28
150.00K shares
10-K · filed 2018-03-28
2016-09-30150.00K shares
10-Q · filed 2016-11-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33
Theriva Biologics, Inc. (TOVX)United States$0.011B
Dare Bioscience, Inc. (DARE)United States$0.011B
Azitra, Inc. (AZTR)United States$0.010B-0.81
Medicus Pharma Ltd. (MDCX)$0.010B
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
Aprea Therapeutics, Inc. (APRE)United States$0.010B-0.78
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92